EW
Edwards Lifesciences Exceeds Expectations with Strong Q3 2026 Results
Edwards Lifesciences, a global leader in patient-focused medical technologies, has announced its third quarter (Q3) financial results for 2026. The company exceeded expectations with strong performance across both its businesses and regions, driven by its structural heart portfolio. The Q3 sales of $1.72 billion grew 11.2%, a testament